Provided by Tiger Trade Technology Pte. Ltd.

SINOMAB BIO-B

1.390
-0.020-1.42%
Volume:2.21M
Turnover:3.10M
Market Cap:1.93B
PE:-14.09
High:1.420
Open:1.410
Low:1.380
Close:1.410
52wk High:3.760
52wk Low:1.160
Shares:1.39B
HK Float Shares:1.39B
Volume Ratio:1.00
T/O Rate:0.16%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.099
ROE:-29.96%
ROA:-9.63%
PB:3.29
PE(LYR):-14.09
PS:291.98

Loading ...

Sinomab Bioscience posts unchanged share capital and maintains public float in April 2026 monthly return

Bulletin Express
·
May 06

SinoMab BioScience releases 2025 ESG report

Reuters
·
Apr 27

SinoMab BioScience unveils 2026 AGM agenda: board changes, 10% share buy-back mandate and 20% issuance limit

Bulletin Express
·
Apr 27

SinoMab BioScience announces annual general meeting

Reuters
·
Apr 27

SinoMab BioScience publishes 2025 annual report

Reuters
·
Apr 27

君实生物(SINOMAB BIO-B)2025年显著减亏,股本增长强化资金实力

Bulletin Express
·
Apr 27

Sinomab Bioscience Maintains 1.39 Billion Outstanding Shares in March 2026, Grants 11.57 Million New Options

Bulletin Express
·
Apr 08

BRIEF-Hainan Haiyao Plans To Unload Stake In Sinomab Bioscience

Reuters
·
Apr 03

Hainan Haiyao Says Co Plans to Unload up to 5% Stake in SinoMab BioScience Ltd

THOMSON REUTERS
·
Apr 03

SM17 Phase 2 Trial for Atopic Dermatitis Administers First Dose in China

Stock News
·
Apr 01

SinoMab doses first patient in China Phase 2 trial of SM17 for atopic dermatitis

Reuters
·
Apr 01

SinoMab BioScience says non-executive directors Chen, Dong resign

Reuters
·
Apr 01

SinoMab BioScience files list of directors with Hong Kong Stock Exchange

Reuters
·
Apr 01

SinoMab Announces Resignation of Two Non-Executive Directors Effective March–April 2026

Bulletin Express
·
Mar 31

SinoMab Announces Updated Board Composition and Committee Assignments

Bulletin Express
·
Mar 31

SINOMAB BIO-B Announces Resignation of Non-Executive Director

Stock News
·
Mar 31

SinoMab Announces Positive Phase 1 Bridging Data for Subcutaneous SM17, Preparing Phase 2 Atopic Dermatitis Trial

Bulletin Express
·
Mar 25

Positive Topline Results from SM17 Route Conversion Phase 1 Bridging Study in China

Stock News
·
Mar 25

SinoMab BioScience announces positive topline results for SM17 China Phase 1 route-switch bridging study; AD Phase 2 in China expected to start by mid-FY2026

Reuters
·
Mar 25

SINOMAB BIO-B (03681) Grants 11.5748 Million Share Options

Stock News
·
Mar 24